|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/26/24 BeiGene, Ltd. 10-K 12/31/23 154:20M |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.16M
2: EX-4.6 Instrument Defining the Rights of Security Holders HTML 151K
3: EX-10.16 Material Contract HTML 97K
4: EX-10.21 Material Contract HTML 56K
5: EX-19.1 Report Furnished to Security Holders HTML 65K
6: EX-19.2 Report Furnished to Security Holders HTML 102K
7: EX-21 Subsidiaries List HTML 60K
8: EX-23.1 Consent of Expert or Counsel HTML 42K
9: EX-23.2 Consent of Expert or Counsel HTML 42K
13: EX-97 Clawback Policy re: Recovery of Erroneously HTML 58K
Awarded Compensation
14: EX-99.1 Miscellaneous Exhibit HTML 40K
10: EX-31.1 Certification -- §302 - SOA'02 HTML 44K
11: EX-31.2 Certification -- §302 - SOA'02 HTML 44K
12: EX-32.1 Certification -- §906 - SOA'02 HTML 41K
20: R1 Cover HTML 110K
21: R2 Audit Information HTML 45K
22: R3 Consolidated Balance Sheets HTML 171K
23: R4 Consolidated Balance Sheets (Parenthetical) HTML 49K
24: R5 Consolidated Statements of Operations HTML 122K
25: R6 Consolidated Statements of Comprehensive Loss HTML 66K
26: R7 Consolidated Statements of Cash Flows HTML 160K
27: R8 Consolidated Statements of Shareholders? Equity HTML 118K
28: R9 Organization HTML 47K
29: R10 Summary of Significant Accounting Policies HTML 162K
30: R11 Collaborative and Licensing Arrangements HTML 153K
31: R12 Restricted Cash HTML 49K
32: R13 Investments HTML 82K
33: R14 Inventories, Net HTML 48K
34: R15 Leases HTML 78K
35: R16 Property, Plant and Equipment, Net HTML 62K
36: R17 Intangible Assets HTML 79K
37: R18 Income Taxes HTML 142K
38: R19 Supplemental Balance Sheet Information HTML 80K
39: R20 Debt HTML 122K
40: R21 Product Revenue HTML 78K
41: R22 Loss Per Share HTML 53K
42: R23 Share-Based Compensation HTML 143K
43: R24 Accumulated Other Comprehensive (Loss) Income HTML 63K
44: R25 Shareholders' Equity HTML 50K
45: R26 Restricted Net Assets HTML 44K
46: R27 Employee Benefit Plans HTML 55K
47: R28 Commitments and Contingencies HTML 47K
48: R29 Segment and Geographic Information HTML 71K
49: R30 Pay vs Performance Disclosure HTML 52K
50: R31 Insider Trading Arrangements HTML 99K
51: R32 Summary of Significant Accounting Policies HTML 191K
(Policies)
52: R33 Summary of Significant Accounting Policies HTML 100K
(Tables)
53: R34 Collaborative and Licensing Arrangements (Tables) HTML 139K
54: R35 Restricted Cash (Tables) HTML 48K
55: R36 Investments (Tables) HTML 83K
56: R37 Inventories, Net (Tables) HTML 49K
57: R38 Leases (Tables) HTML 81K
58: R39 Property, Plant and Equipment, Net (Tables) HTML 64K
59: R40 Intangible Assets (Tables) HTML 80K
60: R41 Income Taxes (Tables) HTML 146K
61: R42 Supplemental Balance Sheet Information (Tables) HTML 86K
62: R43 Debt (Tables) HTML 119K
63: R44 Product Revenue (Tables) HTML 108K
64: R45 Loss Per Share (Tables) HTML 52K
65: R46 Share-Based Compensation (Tables) HTML 140K
66: R47 Accumulated Other Comprehensive (Loss) Income HTML 63K
(Tables)
67: R48 Employee Benefit Plans (Tables) HTML 47K
68: R49 Segment and Geographic Information (Tables) HTML 67K
69: R50 Organization (Details) HTML 64K
70: R51 Summary of Significant Accounting Policies - HTML 42K
Investments (Details)
71: R52 Summary of Significant Accounting Policies - HTML 54K
Property, Plant and Equipment (Details)
72: R53 Summary of Significant Accounting Policies - Land HTML 44K
Use Right, Net (Details)
73: R54 Summary of Significant Accounting Policies - HTML 42K
Goodwill and Other Intangible Assets (Details)
74: R55 Summary of Significant Accounting Policies - HTML 42K
Impairment of Long-Lived Assets (Details)
75: R56 Summary of Significant Accounting Policies - HTML 89K
Assets and Liabilities Measured at Fair Value on a
Recurring Basis (Details)
76: R57 Summary of Significant Accounting Policies HTML 55K
-Government Grants (Details)
77: R58 Summary of Significant Accounting Policies - HTML 41K
Segment Information (Details)
78: R59 Summary of Significant Accounting Policies - HTML 79K
Concentration of Risks (Details)
79: R60 Collaborative and Licensing Arrangements - HTML 72K
Recognized Revenue (Details)
80: R61 Collaborative and Licensing Arrangements - HTML 61K
Novartis (Details)
81: R62 Collaborative and Licensing Arrangements - HTML 94K
Ociperlimab Option, Collaboration and License
Agreement and China Broad Market Development
Agreement (Details)
82: R63 Collaborative and Licensing Arrangements - Amgen HTML 86K
(Details)
83: R64 Collaborative and Licensing Arrangements - Funding HTML 52K
Expenses (Details)
84: R65 Collaborative and Licensing Arrangements - HTML 47K
Financing Liability (Details)
85: R66 Collaborative and Licensing Arrangements - Amounts HTML 59K
and Classification of Payments (Income/(Expense)
(Details)
86: R67 Collaborative and Licensing Arrangements - Payment HTML 51K
Classification (Details)
87: R68 Collaborative and Licensing Arrangements - Ensem HTML 46K
Therapeutics, Inc. (Details)
88: R69 Collaborative and Licensing Arrangements - HTML 59K
Shandong Luye Pharmaceutical Co., Ltd (Details
89: R70 Collaborative and Licensing Arrangements - HTML 48K
Shoreline Biosciences, Inc. (Details)
90: R71 Collaborative and Licensing Arrangements - Nanjing HTML 45K
Leads Biolabs, Inc. (Details)
91: R72 Collaborative and Licensing Arrangements - EUSA HTML 45K
Pharma (Details)
92: R73 Collaborative and Licensing Arrangements - HTML 47K
Assembly Biosciences, Inc. (Details)
93: R74 Collaborative and Licensing Arrangements - HTML 51K
Bio-Thera Solutions, Ltd. (Details)
94: R75 Restricted Cash and Investments - Restrictions on HTML 47K
Cash and Cash Equivalents (Details)
95: R76 Restricted Cash - Narrative (Details) HTML 65K
96: R77 Investments - Short-Term Investments (Details) HTML 52K
97: R78 Investments - Equity Securities with/without HTML 80K
Readily Determinable Fair Values and Equity-Method
Investments (Details)
98: R79 Investments - Losses Recognized On The Company's HTML 65K
Investment In Leap (Details)
99: R80 Investments - Fair value of Common Stock and HTML 67K
Warrants (Details)
100: R81 Investments - Investments In Equity Securities HTML 44K
(Details)
101: R82 Investments - Equity Method Investments (Details) HTML 67K
102: R83 Inventories, Net (Details) HTML 49K
103: R84 Leases - Narratives (Details) HTML 50K
104: R85 Leases - Components of Lease Expense (Details) HTML 48K
105: R86 Leases - Supplemental Balance Sheet (Details) HTML 52K
106: R87 Leases - Maturities of Operating Lease Liabilities HTML 59K
(Details)
107: R88 Leases - Other Supplemental Information (Details) HTML 49K
108: R89 Property, Plant and Equipment, Net- Property, HTML 64K
Plant and Equipment, Net (Details)
109: R90 Property, Plant and Equipment, Net - Narratives HTML 42K
(Details)
110: R91 Property, Plant and Equipment, Net - Construction HTML 50K
in Progress (Details)
111: R92 Intangible Assets - Intangible Assets Outstanding HTML 52K
(Details)
112: R93 Intangible Assets - Useful Life (Details) HTML 45K
113: R94 Intangible Assets - Amortization Expense (Details) HTML 47K
114: R95 Intangible Assets - Expected Amortization Expense HTML 64K
(Details)
115: R96 Income Taxes - Income/(Loss) Before Income Taxes HTML 55K
(Details)
116: R97 Income Taxes - Current and Deferred Components HTML 67K
Income Taxes (Details)
117: R98 Income Taxes - Reconciliation of the Statutory HTML 75K
Rate (Details)
118: R99 Income Taxes - Significant Components of Deferred HTML 67K
Tax Assets (Liabilities) (Details)
119: R100 Income Taxes - Narratives (Details) HTML 66K
120: R101 Income taxes - Schedule of Valuation Allowances HTML 48K
(Details)
121: R102 Income Taxes - Gross Unrecognized Tax Benefits HTML 52K
(Details)
122: R103 Supplemental Balance Sheet Information - Schedule HTML 57K
of Prepaid Expenses and Other Current Assets
(Details)
123: R104 Supplemental Balance Sheet Information - Schedule HTML 55K
of Other Non-current Assets (Details)
124: R105 Supplemental Balance Sheet Information - Schedule HTML 54K
of Accrued Expenses and Other Payables (Details)
125: R106 Supplemental Balance Sheet Information - Schedule HTML 51K
of Other Long-term Liabilities (Details)
126: R107 Debt - Short-term and Long-term Debt Obligations HTML 125K
(Details)
127: R108 Debt - Footnotes (Details) HTML 133K
128: R109 Debt - Contractual maturities of debt obligations HTML 53K
(Details)
129: R110 Debt - Narrative (Details) HTML 44K
130: R111 Product Revenue - Product Sales (Details) HTML 71K
131: R112 Product Revenue - Accrued Sales Rebates and HTML 47K
Returns (Details)
132: R113 Loss Per Share (Details) HTML 71K
133: R114 Share-Based Compensation - 2016 Share Option and HTML 57K
Incentive Plan (Details)
134: R115 Share-Based Compensation - 2018 Inducement Equity HTML 51K
Plan (Details)
135: R116 Share-Based Compensation - 2018 Employee Share HTML 61K
Purchase Plan (Details)
136: R117 Share-Based Compensation - Shares Issued Under HTML 62K
Employee Share Purchase Plan (Details)
137: R118 Share-Based Compensation - Options and Restricted HTML 63K
Shares and Restricted Stock Units Vesting Periods
(Details)
138: R119 Share-Based Compensation - Share Option HTML 110K
Rollforward (Details)
139: R120 Share-Based Compensation - Fair Value Assumptions HTML 64K
(Details)
140: R121 Share-Based Compensation - Restricted Share Units HTML 76K
(Details)
141: R122 Share-Based Compensation - Share-based HTML 47K
Compensation Expense (Details)
142: R123 Accumulated Other Comprehensive (Loss) Income HTML 80K
(Details)
143: R124 Shareholders' Equity (Details) HTML 64K
144: R125 Restricted Net Assets (Details) HTML 49K
145: R126 Employee Benefit Plans - Additional Information HTML 58K
(Details)
146: R127 Employee Benefit Plans - Total Expected Benefit HTML 55K
Payments (Details)
147: R128 Commitments and Contingencies (Details) HTML 59K
148: R129 Segment and Geographic Information - Narratives HTML 42K
(Details)
149: R130 Segment and Geographic Information - Schedule of HTML 68K
Revenue by Geographic Area (Details)
151: XML IDEA XML File -- Filing Summary XML 284K
154: XML XBRL Instance -- bgne-20231231_htm XML 3.40M
150: EXCEL IDEA Workbook of Financial Report Info XLSX 208K
16: EX-101.CAL XBRL Calculations -- bgne-20231231_cal XML 324K
17: EX-101.DEF XBRL Definitions -- bgne-20231231_def XML 1.31M
18: EX-101.LAB XBRL Labels -- bgne-20231231_lab XML 2.91M
19: EX-101.PRE XBRL Presentations -- bgne-20231231_pre XML 1.98M
15: EX-101.SCH XBRL Schema -- bgne-20231231 XSD 336K
152: JSON XBRL Instance as JSON Data -- MetaLinks 803± 1.12M
153: ZIP XBRL Zipped Folder -- 0001651308-24-000014-xbrl Zip 2.08M
 | Download this Microsoft® Excel® .xlsx workbook |